Incyte (MEX:INCY) ROCE %: 24.40% (As of Mar. 2026)


MEX:INCY Incyte Corp MEX:INCY
83 GF Score
Price MXN1,676.03
GF Value MXN1,548.84
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Incyte ROCE %?

Incyte MEX:INCY 83 ROCE % is 24.40% as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 83/100 and a GF Value™ of MXN1,548.84 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Incyte's annualized ROCE % for the quarter that ended in Mar. 2026 was 24.40%.

Incyte  (MEX:INCY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Incyte ROCE % Related Terms

Incyte ROCE % Historical Data

* Premium members only.

The historical data trend for Incyte's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte ROCE % Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.54 11.85 15.32 7.67 33.86

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.77 50.10 40.01 29.67 24.40
MEX:INCY
83GF Score
Incyte Corp MEX:INCY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte ROCE % Calculation

Incyte's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=30013.323/( ( (113545.146 - 34241.868) + (125283.175 - 27281.696) )/ 2 )
=30013.323/( (79303.278+98001.479)/ 2 )
=30013.323/88652.3785
=33.86 %

Incyte's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=24825.184/( ( (125283.175 - 27281.696) + (132344.023 - 26862.394) )/ 2 )
=24825.184/( ( 98001.479 + 105481.629 )/ 2 )
=24825.184/101741.554
=24.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 24.40% mean?
Incyte (MEX:INCY) has a ROCE % of 24.40% as of Mar. 2026.
Is Incyte's ROCE % too high?
Incyte's current ROCE % is 24.40%. Overall, Incyte has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Incyte's ROCE % compare to MRNA and ROIV?
Incyte's ROCE % of 24.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Incyte's current ROCE % is 24.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,548.84, compared to a current price of MXN1,676.03 — trading 8.2% above its estimated fair value. The current ROCE % is 24.40%. Incyte's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Incyte (MEX:INCY), the current ROCE % is 24.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 8.2% above its estimated GF Value™ of MXN1,548.84. GuruFocus considers Incyte to be Fairly Valued.

Key valuation signals for MEX:INCY:

  • ROCE %: 24.40%
  • GF Value™: MXN1,548.84 vs. price of MXN1,676.03 (8.2% above fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
83GF Score

Get the complete analysis for MEX:INCY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,548.84
GF Value